Long-term follow-up after a switch to bictegravir, emtricitabine, tenofovir alafenamide (B/F/TAF) from a boosted protease inhibitor-based regimen

被引：0
|
作者：
Rockstroh, J. [1 ]
Molina, J. M. [2 ]
Post, F. [3 ]
Fox, J. [4 ]
Koenig, E. [5 ]
Daar, E. S. [6 ]
Ruane, P. [7 ]
Crofoot, G. [8 ]
Oguchi, G. [9 ]
Creticos, C. [10 ]
Liu, A. [11 ]
Andreatta, K. [11 ]
Graham, H. [11 ]
Brainard, D. [11 ]
Martin, H. [11 ]
机构：
[1] Univ Hosp Bonn, Bonn, Germany
[2] Hop St Louis, Paris, France
[3] Kings Coll Hosp NHS Fdn Trust, London, England
[4] Guys & St Thomas NHS Fdn Trust, London, England
[5] Inst Dominicano Estudios Virol IDEV, Santo Domingo, Dominican Rep
[6] Harbor UCLA Med Ctr, Lundquist Inst, Torrance, CA 90509 USA
[7] Ruane Clin Res Grp Inc, Los Angeles, CA USA
[8] Crofoot Res Ctr, Houston, TX USA
[9] Midland Florida Clin Res Ctr, Deland, FL USA
[10] Howard Brown Hlth Ctr, Chicago, IL USA
[11] Gilead Sci Inc, Foster City, CA USA
来源：
HIV MEDICINE | 2021年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
O005
引用
收藏
页码：5 / 5
页数：1
相关论文
共 50 条
  • [31] Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in treatment-naive people with both HIV-1 and hepatitis B: 3-year outcomes from ALLIANCE
    Avihingsanon, Anchalee
    Lu, Hongzhou
    Leong, Chee Loon
    Hung, Chien-Ching
    Kiertiburanakul, Sasisopin
    Lee, Man-Po
    Supparatpinyo, Khuanchai
    Madera, Sharline
    Wang, Hongyuan
    Hindman, Jason
    Li, Taisheng
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2024, 27 : 323 - 324
  • [32] Switching from a Non-Protease Inhibitor-Based Regimen to the Fixed Dose Combination of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Clinical Practice (vol 16, pg 1975, 2022)
    Ranzenigo, M.
    Gianotti, N.
    Galli, L.
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2022, 16 : 3737 - 3738
  • [33] A daily single-tablet regimen (STR) of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in virologically suppressed adults living with HIV and end-stage renal disease on chronic haemodialysis
    Eron, J. J.
    Wilkin, A.
    Ramgopal, M.
    Osiyemi, O.
    McKellar, M.
    Slim, J.
    Asmuth, D.
    German, P.
    Blair, C.
    Carter, C. C.
    Brainard, D. M.
    Collins, S. E.
    Gohlar, G.
    Martin, H.
    HIV MEDICINE, 2021, 22 : 24 - 25
  • [34] Efficacy and safety of switching from boosted protease inhibitor plus emtricitabine/tenofovir disoproxil fumarate regimens to the single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in virologically suppressed, HIV-1-infected adults through 24 weeks: EMERALD study
    Molina, J-M
    Gallant, J.
    Orkin, C.
    Negredo, E.
    Bhatti, L.
    Gathe, J.
    Van Landuyt, E.
    Lathouwers, E.
    Hufkens, V.
    Vanveggel, S.
    Opsomer, M.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2017, 20 : 28 - 28
  • [35] Association between fentanyl use and virologic suppression in an HIV-infected cohort of people who use/inject drugs (PWID): results from a bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) switch study
    Conway, B.
    Yi, S.
    Sharma, S.
    Yung, R.
    Truong, D.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 121 - 122
  • [36] Three-year follow-up of protease inhibitor-based regimen simplification in HIV-infected patients
    Martinez, Esteban
    Arnaiz, Juan A.
    Podzamczer, Daniel
    Dalmau, David
    Ribera, Esteban
    Domingo, Pere
    Knobel, Hernando
    Leyes, Maria
    Pedrol, Enric
    Force, Luis
    de Lazzari, Elisa
    Gatell, Jose M.
    AIDS, 2007, 21 (03) : 367 - 369
  • [37] Starting or switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in clinical practice: pooled 12-month (12M) results from the global BICSTaR study
    Spinner, C.
    Stoehr, A.
    Wong, A.
    De Wet, J.
    Zeggagh, J.
    Hocqueloux, L.
    Welzen, B. V.
    Heinzkill, M.
    Sahali, S.
    Cornejo, A.
    Ramroth, H.
    Haubrich, R.
    Thorpe, D.
    Lambert, J.
    Kim, C.
    HIV MEDICINE, 2021, 22 : 24 - 24
  • [38] Starting or switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in clinical practice: pooled 12-month (12M) results from the global BICSTaR study
    Spinner, Christoph
    Stoehr, Albrecht
    Wong, Alexander
    de Wet, Joss
    Zeggagh, Jeremy
    Hocqueloux, Laurent
    van Welzen, Berend
    Heinzkill, Marion
    Sahali, Sabrinel
    Cornejo, Almudena Torres
    Ramroth, Heribert
    Haubrich, Richard
    Thorpe, David
    Kim, Connie
    INFECTION, 2021, 49 (SUPPL 1) : S16 - S16
  • [39] Immuno-virological and Clinical Follow-up of Persons Living With HIV-2 (PWHIV-2) Receiving Bictegravir/Emtricitabine/Tenofovir Alafenamide Fumarate (BIC/FTC/TAF): A Retrospective Study
    Joly, Veronique
    Ferre, Valentine M.
    Le Hingrat, Quentin
    Peytavin, Gilles
    Cresta, Melanie
    Charpentier, Charlotte
    Digumber, Marc
    Damond, Florence
    Yazdanpanah, Yazdan
    Matheron, Sophie
    Descamps, Diane
    Ghosn, Jade
    CLINICAL INFECTIOUS DISEASES, 2024,
  • [40] Patient-reported outcomes (PROs) after 1 year of routine clinical practice with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in people living with HIV (PLWH): the BICSTaR cohort
    Knechten, H.
    Milinkovic, A.
    Stephan, C. C.
    Brunetta, J.
    Trottier, B.
    Bonnet, F.
    Duvivier, C.
    Welzen, B. V.
    Mack, F.
    Tossonian, H.
    Thorpe, D.
    Cornejo, A. T.
    Marongiu, A.
    Curbelo, R.
    HIV MEDICINE, 2021, 22 : 31 - 32
12345